Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SLOG + allogeneic NK cell
- Development stage
- Unknown
- Lead developer
- National Health Research Institutes
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Oral, Intravenous
01
Overview
SLOG + allogeneic NK cell refers to a combination therapy consisting of the chemotherapy regimen SLOG (S-1, leucovorin, oxaliplatin, and gemcitabine) together with an infusion of allogeneic natural killer (NK) cells. In clinical trials such as those using "Allogeneic Magicell-NK," the NK cells are derived from healthy donors and expanded ex vivo before being administered intravenously. The mechanism of action involves cytotoxic activity against tumor cells by both chemotherapeutics and immune-mediated killing via donor-derived NK cells. This combination is being investigated primarily as adjuvant therapy following surgical resection for pancreatic ductal adenocarcinoma (PDA) or cholangiocarcinoma[1][3]. The approach aims to enhance anti-tumor efficacy by combining direct cytotoxic effects of chemotherapy with immunotherapy that leverages innate immune responses.
- Other names
- S-1S1S 1leucovorinoxaliplatingemcitabineMagicell-NK
02
Targets
MAGEA8 (Melanoma-associated antigen 8)
Beyond the preview
Go deeper on SLOG + allogeneic NK cell.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SLOG + allogeneic NK cell.